During the corresponding time, Revvity Inc recorded a revenue increase by 1.31 % year on year, sequentially revenue grew by 2.61 %. While revenue at the Revvity Inc's corporate clients
Revvity’s Strategic Moves to Enhance Scientific Software and Genomic Diagnostics WALTHAM, Mass. In an ambitious bid to bolster its position in the analytical and genomic landscapes, Revvity, Inc. (NYSE: RVTY), has announced significant operational advancements through targeted acquisitions and strategic collaborations. The company is steadfastly committed to creating a seamless integration of scientific technology and actionable data, with the latest developments signaling a pivotal expansion of its core offerings.Firstly, Revvity has entered into a definitive agreement to acquire ACD/Labs, a renowned global provider of scientific software that excels in analytical characterization and molecular design, ...
Revvity Inc. Announces Strategic Developments: Investor Day, New TB Testing Automation, and Upcoming Financial Call WALTHAM, Mass. Revvity, Inc. (NYSE: RVTY), a pioneering force in the biotechnological landscape, has announced a trifecta of significant corporate initiatives, emphasizing its commitment to innovation and stakeholder engagement. These announcements include an upcoming Investor Day, strategic organizational adjustments, the launch of an advanced automated tuberculosis testing platform, and plans for an earnings call that will discuss financial performance. Investor Day: A Spotlight on Corporate ProgressRevvity will host its highly anticipated Investor Day on November 21, 2024 , at 9:00 a.m...
Introducing Signals ChemDraw: Revolutionizing Chemistry Communication in the CloudWALTHAM, Mass. - Revvity, Inc. (NYSE: RVTY) is making waves once again in the field of chemical research and development with the launch of their newest offering, Signals ChemDraw. This advanced chemistry suite, developed by Revvity s software and informatics division, Revvity Signals Software, aims to redefine the way researchers, academics, and professionals in the pharmaceutical and non-pharmaceutical industries communicate and collaborate on complex chemical concepts.ChemDraw, an integral part of the renowned Revvity Signals Software portfolio, introduces a cloud-native solution that streamlines and enhances chemistry commu...
Revvity, Inc. (NYSE: RVTY), a prominent player on the NYSE stage, has recently announced its intent to share the company s financial performance for the fourth quarter and the full year of 2023. Committed to maintaining transparency in its financial proceedings, Revvity disclosed its plan of releasing these significant figures before the market opens on Thursday, February 1, 2024.In a calculated move delineating the company s dedication to its investor base, Revvity is also set to host a conference call on the same day detailing and discussing these imminent results. Scheduled at 8:00 a.m. Eastern Time, the audio webcast will be accessible live and promises to deliver an updated and comprehensive overview of...
Sources:
Revvity Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Revvity Inc’s corporate clients.
For your research, we’ve provided 9 tables on Revvity Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
162.38 %